Short Interest in Replimune Group, Inc. (NASDAQ:REPL) Decreases By 16.5%

Replimune Group, Inc. (NASDAQ:REPL) was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5% from the November 15th total of 6,680,000 shares. Based on an average daily trading volume, of 828,800 shares, the days-to-cover ratio is presently 6.7 days.

Insider Buying and Selling

In related news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total transaction of $78,111.88. Following the sale, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This trade represents a 6.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its position in Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the period. Braidwell LP boosted its holdings in Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock valued at $33,656,000 after acquiring an additional 2,057,460 shares during the period. State Street Corp grew its position in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock worth $25,647,000 after acquiring an additional 1,182,181 shares during the last quarter. Baker BROS. Advisors LP increased its stake in Replimune Group by 10.0% in the 3rd quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its position in Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock valued at $8,371,000 after purchasing an additional 238,747 shares during the last quarter. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on REPL. Jefferies Financial Group increased their price target on Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, December 4th. Roth Mkm started coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. BMO Capital Markets raised their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $17.29.

Replimune Group Stock Performance

Replimune Group stock opened at $12.55 on Monday. The firm has a market capitalization of $858.67 million, a PE ratio of -4.11 and a beta of 1.26. Replimune Group has a 1-year low of $4.92 and a 1-year high of $17.00. The firm’s 50 day simple moving average is $12.19 and its 200 day simple moving average is $10.53. The company has a current ratio of 10.11, a quick ratio of 10.11 and a debt-to-equity ratio of 0.18.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, analysts expect that Replimune Group will post -2.91 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.